<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01725984</url>
  </required_header>
  <id_info>
    <org_study_id>MC1201</org_study_id>
    <nct_id>NCT01725984</nct_id>
  </id_info>
  <brief_title>AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up</brief_title>
  <official_title>AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Medical Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center retrospective chart review of AdVance and AdVance XP subject data, combined
      with prospective follow-up of the same subjects to confirm continence, adverse event, and
      quality of life status. This study includes patients previously implanted with an AdVance or
      AdVance XP male sling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center retrospective chart review of AdVance and AdVance XP subject data, combined
      with prospective follow-up of the same subjects to confirm continence, adverse event, and
      quality of life status. This study includes patients previously implanted with an AdVance or
      AdVance XP male sling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use</measure>
    <time_frame>3 Months Post Procedure</time_frame>
    <description>Evaluate the proportion of subjects with a ≥50% reduction in pads per day use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Cured, Improved, or Failed Based on Reported Pad Per Day Use</measure>
    <time_frame>3 months Post Procedure</time_frame>
    <description>Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and ≥50% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</measure>
    <time_frame>Baseline</time_frame>
    <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the 24-hour Pad Weight at the Final Prospective Follow-up Visit</measure>
    <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
    <description>Percentage of subjects at a given weight for their 24-hour pad weight test at the final prospective follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quality of Life Scores as Compared to Baseline for I-QOL, ICIQ-SF, and Summary of Values for the PGI-I. Measured From Baseline to Prospective Follow.</measure>
    <time_frame>Baseline to Prospective Follow Up (up to 36 months)</time_frame>
    <description>The Incontinence Quality of Life Questionnaire (I-QOL) is a 22 questionnaire that evaluates a subject's quality of life with respect to urinary problems/incontinence. A lower score correlates with more severe incontinence, and an increase from baseline indicates an improvement in quality of life. The score scale is 0 - 100.
The International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) is a 4 question tool that quantifies the impact on quality of life from incontinence. A decrease from baseline to follow-up indicates an improvement in quality of life. The score scale is 1-21.
The Patient Global Impression of Improvement (PGI-I) questionnaire is a single question instrument that assess a subject's perception of the disease impact on their quality of life. Completed at the last visit, a lower score indicates a better perception from the patient. Scale from 1 to 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events Reported Between Arms</measure>
    <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
    <description>Evaluate the occurrence of all AdVance /AdVance XP AEs, as well as those reported as serious, intra-operative, device or procedure related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use</measure>
    <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
    <description>Evaluate the proportion of subjects with a ≥50% reduction in pads per day use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Cured, Improved, or Failed Based on Reported Pad Per Day Use</measure>
    <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
    <description>Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and ≥50% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</measure>
    <time_frame>3 Months Post Procedure</time_frame>
    <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</measure>
    <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
    <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Urinary Incontinence, Stress</condition>
  <condition>Intrinsic Sphincter Deficiency</condition>
  <arm_group>
    <arm_group_label>AdVance</arm_group_label>
    <description>Subjects previously implanted with the AdVance Male Sling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AdVance XP</arm_group_label>
    <description>Subjects previously implanted with the AdVance XP male sling</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male subject ≥40 years of age who received the AdVance male sling after January 1, 2010 or
        the AdVance XP male sling after July 1, 2010 for the treatment of post prostatectomy SUI at
        one institution in Munich, Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Valid, written informed consent has been obtained

          2. Male subject ≥40 years of age who received the AdVance male sling after January 1,
             2010 or the AdVance XP male sling after July 1, 2010 for the treatment of post
             prostatectomy SUI

          3. Pad use of 1 to 8 pads per day prior to sling placement (subjects who used only a dry
             prophylactic pad or safety liner at baseline will not be included)

          4. External (distal) sphincter contractility and a coaptive zone of ≥ 1cm confirmed by
             endoscopic view prior to sling placement

          5. Primary etiology of SUI resulting from radical prostatectomy including, simple open
             prostatectomy, robotic or laparoscopic prostatectomy

        Exclusion Criteria:

          1. Pad use of more than 8 pads per day prior to sling placement for incontinence
             management

          2. Urine loss while lying in bed prior to sling placement

          3. Treatment with a urethral sling system, an AMS Sphincter 800®, or any implanted device
             for the treatment of urinary incontinence (not including bulking agents) prior to
             sling placement

          4. TURP procedure prior to sling placement

          5. Urge predominant incontinence prior to sling placement

          6. Past or current neurological disorder (e.g. neurogenic bladder, multiple sclerosis,
             Parkinson's disease)

          7. History of connective tissue or autoimmune conditions

          8. Past or current condition of compromised immune system

          9. Placement of an inflatable penile prosthesis (IPP) after sling placement

         10. Post void residual of &gt;50 ml prior to sling placement
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricarda Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig‐Maximilians Universität (LMU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig‐Maximilians Universität (LMU)</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2012</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2015</results_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male Incontinence</keyword>
  <keyword>AdVance Male Sling</keyword>
  <keyword>AdVance XP Male Sling</keyword>
  <keyword>Male Sling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>140 subjects were screened for inclusion into the study. 80 total subjects met all inclusion and none of the exclusion criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AdVance</title>
          <description>Subjects previously implanted with the AdVance Male Sling</description>
        </group>
        <group group_id="P2">
          <title>AdVance XP</title>
          <description>Subjects previously implanted with the AdVance XP male sling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AdVance</title>
          <description>Subjects previously implanted with the AdVance Male Sling</description>
        </group>
        <group group_id="B2">
          <title>AdVance XP</title>
          <description>Subjects previously implanted with the AdVance XP male sling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="4.9"/>
                    <measurement group_id="B2" value="68.8" spread="5.3"/>
                    <measurement group_id="B3" value="69.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use</title>
        <description>Evaluate the proportion of subjects with a ≥50% reduction in pads per day use</description>
        <time_frame>3 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use</title>
          <description>Evaluate the proportion of subjects with a ≥50% reduction in pads per day use</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2"/>
                    <measurement group_id="O2" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Cured, Improved, or Failed Based on Reported Pad Per Day Use</title>
        <description>Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and ≥50% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective follow-up visit</description>
        <time_frame>3 months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Cured, Improved, or Failed Based on Reported Pad Per Day Use</title>
          <description>Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and ≥50% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective follow-up visit</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</title>
        <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</title>
          <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Pad per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 or more Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the 24-hour Pad Weight at the Final Prospective Follow-up Visit</title>
        <description>Percentage of subjects at a given weight for their 24-hour pad weight test at the final prospective follow-up visit.</description>
        <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the 24-hour Pad Weight at the Final Prospective Follow-up Visit</title>
          <description>Percentage of subjects at a given weight for their 24-hour pad weight test at the final prospective follow-up visit.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;= 10g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="68.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10g - 50g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 50g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Quality of Life Scores as Compared to Baseline for I-QOL, ICIQ-SF, and Summary of Values for the PGI-I. Measured From Baseline to Prospective Follow.</title>
        <description>The Incontinence Quality of Life Questionnaire (I-QOL) is a 22 questionnaire that evaluates a subject's quality of life with respect to urinary problems/incontinence. A lower score correlates with more severe incontinence, and an increase from baseline indicates an improvement in quality of life. The score scale is 0 - 100.
The International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) is a 4 question tool that quantifies the impact on quality of life from incontinence. A decrease from baseline to follow-up indicates an improvement in quality of life. The score scale is 1-21.
The Patient Global Impression of Improvement (PGI-I) questionnaire is a single question instrument that assess a subject's perception of the disease impact on their quality of life. Completed at the last visit, a lower score indicates a better perception from the patient. Scale from 1 to 7.</description>
        <time_frame>Baseline to Prospective Follow Up (up to 36 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Scores as Compared to Baseline for I-QOL, ICIQ-SF, and Summary of Values for the PGI-I. Measured From Baseline to Prospective Follow.</title>
          <description>The Incontinence Quality of Life Questionnaire (I-QOL) is a 22 questionnaire that evaluates a subject's quality of life with respect to urinary problems/incontinence. A lower score correlates with more severe incontinence, and an increase from baseline indicates an improvement in quality of life. The score scale is 0 - 100.
The International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) is a 4 question tool that quantifies the impact on quality of life from incontinence. A decrease from baseline to follow-up indicates an improvement in quality of life. The score scale is 1-21.
The Patient Global Impression of Improvement (PGI-I) questionnaire is a single question instrument that assess a subject's perception of the disease impact on their quality of life. Completed at the last visit, a lower score indicates a better perception from the patient. Scale from 1 to 7.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IQOL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" spread="21.0"/>
                    <measurement group_id="O2" value="45.6" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IQOL 3 Month FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="21.5"/>
                    <measurement group_id="O2" value="85.4" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IQOL Prospective FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="21.7"/>
                    <measurement group_id="O2" value="86.8" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICIQ-SF Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="5.1"/>
                    <measurement group_id="O2" value="15.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICIQ-SF 3 Month FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="5.4"/>
                    <measurement group_id="O2" value="4.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICIQ-SF Prospective FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="5.6"/>
                    <measurement group_id="O2" value="5.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGI-I Prospective FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.1"/>
                    <measurement group_id="O2" value="1.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events Reported Between Arms</title>
        <description>Evaluate the occurrence of all AdVance /AdVance XP AEs, as well as those reported as serious, intra-operative, device or procedure related adverse events</description>
        <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Reported Between Arms</title>
          <description>Evaluate the occurrence of all AdVance /AdVance XP AEs, as well as those reported as serious, intra-operative, device or procedure related adverse events</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Number of AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Procedure Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intra-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use</title>
        <description>Evaluate the proportion of subjects with a ≥50% reduction in pads per day use</description>
        <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use</title>
          <description>Evaluate the proportion of subjects with a ≥50% reduction in pads per day use</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Cured, Improved, or Failed Based on Reported Pad Per Day Use</title>
        <description>Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and ≥50% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective follow-up visit</description>
        <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Cured, Improved, or Failed Based on Reported Pad Per Day Use</title>
          <description>Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and ≥50% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective follow-up visit</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</title>
        <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
        <time_frame>3 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</title>
          <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1"/>
                    <measurement group_id="O2" value="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Pad per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</title>
        <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
        <time_frame>Prospective follow-up to 36 Months Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AdVance</title>
            <description>Subjects previously implanted with the AdVance Male Sling</description>
          </group>
          <group group_id="O2">
            <title>AdVance XP</title>
            <description>Subjects previously implanted with the AdVance XP male sling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects in Each Pre-defined Range of Pads Per Day Use</title>
          <description>Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:
0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Pad per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 or more Pads per Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected during the study conductance between August 2012 and January 2013 (6 Months), and were reported from subjects between January 2010 to January 2013 (3 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AdVance</title>
          <description>Subjects implanted with the AdVance Male Sling</description>
        </group>
        <group group_id="E2">
          <title>AdVance XP</title>
          <description>Subjects implanted with the AdVance XP Male Sling</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence De Novo (Urge)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain/Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Post-Void Residual (PVR)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Superficial Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence- De Novo (Stress)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence- De Novo (Urge)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence- Worsening Urge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ricarda Bauer</name_or_title>
      <organization>Ludwig Maximilian Universität</organization>
      <phone>+49 89 7095</phone>
      <email>Ricarda.Bauer@med.uni-muenchen.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

